scispace - formally typeset
K

Kala Visvanathan

Researcher at Johns Hopkins University

Publications -  295
Citations -  14979

Kala Visvanathan is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 55, co-authored 255 publications receiving 11825 citations. Previous affiliations of Kala Visvanathan include Johns Hopkins University School of Medicine & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Leisure Time Physical Activity and Mortality: A Detailed Pooled Analysis of the Dose-Response Relationship

TL;DR: In this article, the authors quantify the dose-response association between leisure time physical activity and mortality and define the upper limit of benefit or harm associated with increased levels of physical activity.
Journal ArticleDOI

Leisure Time Physical Activity of Moderate to Vigorous Intensity and Mortality: A Large Pooled Cohort Analysis

TL;DR: Analyzing data from over 650,000 individuals, Dr. Steven Moore and colleagues report that greater amounts of leisure-time physical activity were associated with higher life expectancy across a wide range of activity levels and body mass index groups.
Journal ArticleDOI

Detectable clonal mosaicism and its relationship to aging and cancer

Kevin B. Jacobs, +208 more
- 01 Jun 2012 - 
TL;DR: In an analysis of 31,717 cancer cases and 26,136 cancer-free controls from 13 genome-wide association studies, this paper observed large chromosomal abnormalities in a subset of clones in DNA obtained from blood or buccal samples.
Journal ArticleDOI

Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021

Mary B. Daly, +33 more
TL;DR: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies as mentioned in this paper.
Journal ArticleDOI

Beta Blockers and Breast Cancer Mortality: A Population- Based Study

TL;DR: Evidence in humans is provided to support preclinical observations suggesting that inhibiting the β₂-adrenergic signaling pathway can reduce breast cancer progression and mortality.